*Together with Monument Traders Alliance
Good day, 360!
Here are some of our top movers today. And don’t forget to join us in Market Masters – the hottest trading room around 🔥. Be the best prepared trader on the Street!
FOCUS LIST🔎
UAVS – Up over 70% in the pre-market after announcing pricing of $6.5 million public offering
SLXN – Up over 50% in pre after reporting breakthroughs from SIL-204 preclinical studies
SGMT – Up over 11% in pre after receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
*Together with Monument Traders Alliance
Join America’s #1 Fast-Trading Expert as He Goes LIVE With a Brand-New Trading Development
Wednesday, Oct 2nd 2pm EST
HOTLIST🔥
UAVS – Up over 70% in the pre-market after announcing pricing of $6.5 million public offering
AgEagle Aerial Systems Inc. (UAVS), through its subsidiaries, designs and delivers autonomous unmanned aerial systems worldwide. The company operates in three segments: Drones; Sensors; and Software-as-a-Service (SaaS).
In the pre-market this morning, the company announced the pricing of a public offering with gross proceeds to the Company expected to be approximately $6.5 Million, before deducting placement agent fees and other estimated offering expenses payable by the Company.
The offering consists of 26,900,000 Units, each consisting of one (1) share of our common stock, $0.001 par value per share (the “Common Stock”) or one Pre-Funded Warrant to purchase one share of Common stock, one Series A warrant (“Series A Warrant”) to purchase one share of Common Stock and one Series B warrant (“Series B Warrant”) to purchase one share of Common Stock.
The public offering price per Unit is $0.24 (or $0.239 for each Unit with a Pre-Funded Warrant, which is equal to the public offering price per Unit with a share of Common Stock to be sold in the offering minus an exercise price of $0.001 per Pre-Funded Warrant). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full.
The initial exercise price of each Series B Warrant is $0.50 per share of common stock. The Series B Warrants are exercisable immediately and expire five years from the closing date of this public offering.
The stock traded up over 70% in the pre-market in reaction to the news.
The first target for bulls is the pre-market high at $0.2295. Beyond that $0.24, $0.25, $0.33 and $0.40 come into play.
Below $0.2295, targets to the downside are $0.18, $0.1437, $0.12 and then $0.10.
SLXN – Up over 50% in pre after reporting breakthroughs from SIL-204 preclinical studies
Silexion Therapeutics Corp (SLXN) is a biopharmaceutical company that discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors.
In the pre-market this morning, the company announced new preclinical findings for SIL-204, its second-generation siRNA candidate, following the optimization of its extended-release formulation.
These latest findings demonstrate that the latest SIL-204-microparticle formulation can inhibit the growth and induce necrosis of the human pancreatic cell line that bears the KRAS G12D mutation xenotransplanted into mice. Given that this mutation constitutes the largest segment of pancreatic cancer subtypes, it represents a significant in the development of SIL-204.
The stock traded up over 50% in the pre-market in reaction to the news.
The $0.75 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $0.80, $0.85, $0.90 and then the pre-market high at $0.96. Beyond that, $1.15, $1.27 and $1.40 come into play.
Below $0.75, targets to the downside are $0.65 and then a gap fill at $0.5252.
“Hit MONSTER winners when stocks gap down!” – See how withBryan Bottarelli Wed. Oct 2nd, 2pm ET.
*proud affiliate for Monument Traders Alliance
SGMT – Up over 11% in pre after receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
Sagimet Biosciences Inc. (SGMT) is a clinical-stage biopharmaceutical company that develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States.
In the pre-market this morning, the company announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to denifanstat for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
Preparations are ongoing to initiate Phase 3 program for denifanstat by the end of 2024.
The stock traded up over 11% in the pre-market in reaction to the news.
The first target for bulls is the pre-market high at $3.29. Beyond that, $3.50, $3.70, $3.94 and $4.20 come into play.
Below $3.29, targets to the downside are $3, and then a gap fill at $2.77.
MARKET NEWS 📰
P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas!
Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
*Sponsored content: We’re a proud affiliate for Monument Traders Alliance Live, meaning if you click a link for a product or service, we may earn a commission at no extra cost to you. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals.
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication
